PCN212 PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER

Determining the optimal treatment pathway for metastatic colorectal cancer (mCRC) patients is challenging given the many possible treatment combinations and sequences. Simulation models combining patient and disease characteristics to estimate effectiveness of treatment sequencing strategies have potential to guide treatment decisions. As a first step to a comprehensive sequencing model, we simulated progression-free survival (PFS) and overall...